Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ABVC BioPharma, Inc. (ABVC) has issued an update.
ABVC BioPharma has announced corrections to a previous press release concerning their licensing deals with AiBtl, ForSeeCon, and OncoX. The company clarified that the potential aggregate license fee is $19 million, not $24 million as initially reported. Furthermore, the expected total cash payment from these licensees is $18.7 million, contrary to the previously stated $23.7 million.
For an in-depth examination of ABVC stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money